Santersus secures its second FDA Breakthrough Device Designation for NucleoCapture, now in severe lupus (SLE)—a new step toward non-immunosuppressive therapies. #News #FDA #BreakthroughDevice #Lupus #Autoimmune #MedTech #Biotech #Innovation #ClinicalTrials

















